Search results
Results from the WOW.Com Content Network
Methylprednisolone suleptanate, sold under the brand names Medrosol and Promedrol, is a synthetic glucocorticoid corticosteroid and a corticosteroid ester—specifically, the C21 suleptanate 21-(8-(methyl-(2-sulfoethyl)amino)-1,8-dioxooctanoate) ester of methylprednisolone. [1] [2] It acts as a prodrug of methylprednisolone. [3]
Methylprednisolone succinate, sold under the brand name Solu-Medrol among others, is a synthetic glucocorticoid corticosteroid and a corticosteroid ester—specifically the C21 succinate ester of methylprednisolone—which is used by intravenous administration.
Oral methylprednisolone has a moderate distribution into tissue at 1.38L/kg. [39] Methylprednisolone is primarily eliminated by hepatic metabolism and renal excretion of metabolites; with renal excretion of unchanged methylprednisolone at only 1.3–9.2%. [39] Methylprednisolone can be interconverted with methylprednisone. [32]
The American Diabetes Association defines the following criteria for the diagnosis of diabetes: a HbA1c of 6.5%, an 8-hour fasting blood glucose of 7.0 mmol/L (126 mg/dL), a 2-hour oral glucose tolerance test (OGTT) of ≥ 11.1 mmol/L (200 mg/dL), or in patients exhibiting hyperglycemic symptoms, a random plasma glucose of ≥ 11.1 mmol/L (200 mg/dL).
[1] [4] [5] Methylprednisolone acetate was previously suspended with polyethylene glycol but is no longer formulated with this excipient due to concerns about possible toxicity. [6] [8] Depo methylprednisolone acetate is a depot injection and is absorbed slowly with a duration of weeks to months with a single intramuscular injection. [5]
The first patient was treated using the Edmonton protocol in March 1999. The protocol was first published in the New England Journal of Medicine in July 2000. [1] The NEJM report was exciting for the diabetes field because the seven patients undergoing the Edmonton protocol remained insulin-independent after an average of 12 months. [citation ...
Prednisolone is a corticosteroid, a steroid hormone used to treat certain types of allergies, inflammatory conditions, autoimmune disorders, and cancers, electrolyte imbalances and skin conditions.
In pharmacokinetics, the rate of infusion (or dosing rate) refers not just to the rate at which a drug is administered, but the desired rate at which a drug should be administered to achieve a steady state of a fixed dose which has been demonstrated to be therapeutically effective. Abbreviations include K in, [1] K 0, [2] or R 0.